This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Amarin Is Really Good At Delays, Drug Launches Not So Much

BEDMINSTER, NJ ( TheStreet) --Here we go again. Amarin (AMRN - Get Report) disclosed yet another delay Thursday. This time, the company is putting off a decision on hiring a sales force to sell Vascepa until the first half of December. Amarin had promised an announcement by the end of November.

For those keeping score at home, FDA approved Amarin's triglyceride-lowering, prescription-grade fish oil pill 126 days ago. After all the time, effort and cost to get a drug approved, most companies are chomping at the bit to start selling within days or a few weeks of approval.

Not Amarin, which apparently believes Vascepa needs aging, like fine red wine, before it hits the market. Does fish oil smell any better if it sits around for four months?

Amarin bulls will disagree, of course. They believe the company is both a victim of FDA's stubbornness over the still-unresolved NCE (market exclusivity) issue, and sneaky smart because negotiations for a blockbuster buyout deal must be imminent, hence all the delays.

It's no coincidence a decision on Vascepa's commercial launch is being delayed until mid-December since that coincides with FDA's next-scheduled update of the Orange Book. Amarin is clearly hoping (praying) that FDA gives in and grants NCE status to Vascepa.

How this helps Amarin avoid the disastrous "go it alone" Vascepa launch isn't clear. If Vascepa is the billion-dollar generating blockbuster drug the company and its supporters claim, why hasn't a Big Pharma partner already gobbled up marketing rights?

We know the uncertainty around Vascepa's NCE status has hurt Amarin -- management acknowledged this on its last conference call -- but that shouldn't have stopped the company and an interested, motivated suitor from negotiating a deal with a contingent value right (CVR) tied to Vascepa's NCE status.

For example, Big Pharma X agrees to buy Amarin today for $15 per share. If Vascepa wins NCE status later, Big Pharma X will pay an additional $10 per share to Amarin shareholders.

We've seen CVR-incentivized deals used commonly in bio-pharma. Celgene (CELG) created a CVR tied to the cancer drug Abraxane when it acquired Abraxis BioScience. Sanofi (SNY) and Genzyme negotiated a CVR as part of their buyout deal.

Amarin should be the poster child for a CVR-type acquisition yet so far, no deal has been announced. To me, that's telling, and not in a good way.

What we get instead from Amarin is delay after delay layered on top of more delays. I commend Amarin bulls for their patience and relentless optimism. I just don't share the sentiment.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AMRN $2.41 6.64%
AAPL $123.25 -0.80%
FB $83.30 0.35%
GOOG $548.34 -1.23%
TSLA $185.00 -2.84%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs